Press release – Sobrera Completes Oversubscribed Financing Round
Sobrera Pharma AB Completes Oversubscribed Financing Round, Ahead of Key Development Milestones
Gothenburg, Sweden – February 5, 2026
Sobrera Pharma AB today announced the successful completion of a financing round, exceeding its original target of SEK 20 million. The transaction significantly strengthens the company’s financial position as it enters its next phase of development.
The financing attracted strong interest from both existing and new investors and included participation from capital-strong investors across several countries, many of whom bring substantial life science and pharmaceutical expertise.
“Exceeding our funding target is a strong validation of Sobrera’s strategy and long-term potential,” said Jan-Fredrik Backman, Chairman of the Board.
“Combined with the recent strengthening of our Board, we now have both the financial resources and the governance structure needed to execute on our upcoming milestones.”
The proceeds from the financing will support Sobrera over the next 18 months and enable the company to advance its lead candidate, SO-001, through several critical activities, including formulation development, patent filings, U.S. and EU regulatory interactions, and preparations to progress the program toward Phase 2b readiness.
Ann-Charlotte Rosendahl, CEO of Sobrera Pharma AB, commented:
“This successful financing allows us to fully focus on execution. With a strengthened balance sheet and an increasingly international, highly experienced investor base, Sobrera is well positioned to advance its development plan and continue building momentum”
With strong financial backing and growing international support, Sobrera continues to advance toward its next set of value-creating milestones.
About Sobrera Pharma AB
Sobrera Pharma AB is a privately held pharmaceutical company developing innovative treatments for Alcohol Use Disorder (AUD), addressing major unmet medical needs through differentiated and scalable therapeutic approaches.
For more information, please visit: www.sobrera.com
About AUD
Alcohol Use Disorder (AUD) affects an estimated 280 million people worldwide, yet fewer than 3% receive pharmacological treatment. Despite its severe consequences to patients, their families and society, the condition remains one of the most under-treated areas in medicine, highlighting both a substantial unmet medical need and a significant opportunity for new therapeutic solutions.
Link to Press Release in pdf